Treatment of Non-Small Cell Carcinoma of the Lung by a Combination Chemotherapy with Cyclophosphamide, Vincristine, and Methotrexate, or with Adriamycin, Cyclophosphamide, Vincristine, and Methotrexate.

概要

論文の詳細を見る
Thirty-eight of 89 patients with advanced non-small cell carcinoma of the lung were treated by a combination chemotherapy with cyclophosphamide (CPA) (500 mg/m2), vincristine (VCR) (1mg), and methotrexate (MTX) (20mg/m2), and the remaining fifty-one patients with adriamycin (ADR) (35 mg/m2), CPA (400mg/m2), . VRC (mg) and MTX (20/m2). Response rates were 13%(CR; 2, PR; 2) in the COM group and 13.7%(CR; O, PR; 7) in the ACOM group. Eleven out of 12 patients complaining of severe pain due to multiple bone metastases were afforded. great relief by the ACOM regimen. The median survival time was 10 months in the COM group and 11 months in the ACOM group. There was no statistically significant difference between the two groups (p<0.3). Severe side effects were not observed in either groups but nausea, vomiting, alopecia and myelosuppression were noted more frequently in the ACOM group.
特定非営利活動法人日本肺癌学会の論文